Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study

C Berking; E Livingstone; M Weichenthal; U Leiter; K Wittmann; T Eigentler; P Mohr; F Kiecker; C Loquai; Dirk Debus; R Gutzmer

Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study

C Berking, E Livingstone, M Weichenthal, U Leiter, K Wittmann, T Eigentler, P Mohr, F Kiecker, C Loquai, Dirk Debus, R Gutzmer

Department of Dermatology

Research output: Contribution to journal › Abstract (Journal) › peer-review

2 Citations (Web of Science)

Original language	English
Pages (from-to)	544-+
Journal	ANNALS OF ONCOLOGY
Volume	30
Publication status	Published - 2019
Event	44th Congress of the European-Society-for-Medical-Oncology (ESMO) - Barcelona, SPAIN Duration: 27 Sept 2019 → 1 Oct 2019

Cite this

Berking, C., Livingstone, E., Weichenthal, M., Leiter, U., Wittmann, K., Eigentler, T., Mohr, P., Kiecker, F., Loquai, C., Debus, D., & Gutzmer, R. (2019). Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study. ANNALS OF ONCOLOGY , 30, 544-+.

Berking, C ; Livingstone, E ; Weichenthal, M et al. / Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study. In: ANNALS OF ONCOLOGY 2019 ; Vol. 30. pp. 544-+.

@article{c5c76c6725984794b75b39edcb0b07f3,

title = "Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study",

author = "C Berking and E Livingstone and M Weichenthal and U Leiter and K Wittmann and T Eigentler and P Mohr and F Kiecker and C Loquai and Dirk Debus and R Gutzmer",

year = "2019",

language = "English",

volume = "30",

pages = "544--+",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

note = "44th Congress of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 27-09-2019 Through 01-10-2019",

}

Berking, C, Livingstone, E, Weichenthal, M, Leiter, U, Wittmann, K, Eigentler, T, Mohr, P, Kiecker, F, Loquai, C, Debus, D & Gutzmer, R 2019, 'Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study', ANNALS OF ONCOLOGY , vol. 30, pp. 544-+.

Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study. / Berking, C; Livingstone, E; Weichenthal, M et al.
In: ANNALS OF ONCOLOGY , Vol. 30, 2019, p. 544-+.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study

AU - Berking, C

AU - Livingstone, E

AU - Weichenthal, M

AU - Leiter, U

AU - Wittmann, K

AU - Eigentler, T

AU - Mohr, P

AU - Kiecker, F

AU - Loquai, C

AU - Debus, Dirk

AU - Gutzmer, R

PY - 2019

Y1 - 2019

M3 - Abstract (Journal)

SN - 0923-7534

VL - 30

SP - 544-+

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

T2 - 44th Congress of the European-Society-for-Medical-Oncology (ESMO)

Y2 - 27 September 2019 through 1 October 2019

ER -

Berking C, Livingstone E, Weichenthal M, Leiter U, Wittmann K, Eigentler T et al. Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study. ANNALS OF ONCOLOGY . 2019;30:544-+.